Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

United States ,Italy ,New Jersey ,American ,Roberto Mina ,Ciltacabtagene Autoleucel ,Ying Huang ,Jessie Yeung ,Alexandra Ventura ,American Cancer Society ,Exchange Commission On ,Legend Biotech Corporation ,American Society Of Hematology Annual Meeting ,Clinical Development ,European Organisation For Research ,Janssen Biotech Inc ,Division Of Hematology ,University Of Torino ,Department Of Molecular Biotechnology ,Exchange Commission ,American Society Of Clinical Oncology ,American Society Of Hematology ,Twitter ,Corporate Communications Investor Relations ,Health Sciences ,Linkedin ,Biotech Corporation ,Legend Biotech ,Annual Meeting ,Assistant Professor ,Molecular Biotechnology ,European Organisation ,Cancer Quality ,Life Questionnaire Core ,Multiple Myeloma Symptom ,Impact Questionnaire ,Cytokine Release Syndrome ,Chief Executive Officer ,Important Safety ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Janssen Biotech ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Annual Report ,Reported Outcomes ,Ciltacabtagene Autoleucel Vs Standard ,Lenalidomide Refractory Multiple Myeloma ,Hematology Annual ,Lines Who Received ,Single Infusion ,Ciltacabtagene Autoleucel As Study Treatment ,Updated Efficacy ,Multiple Myeloma ,Early Relapse ,First Line Treatment ,Study Comparing ,Versus Pomalidomide ,Participants With Relapsed ,Chimeric Antigen Receptort Cell ,Participants With Multiple Myeloma ,Statistics About Multiple Myeloma ,Accessed Nov ,Corporate Communications ,Investor Relations ,Public Relations ,Business Wire ,Region ,